Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

10,018 total articles

Endeavor Investor Group Acquires $4.38 Million Stake in Mawson Infrastructure Group Amidst Financial Challenges

Endeavor Investor Group Acquires $4.38 Million Stake in Mawson Infrastructure Group Amidst Financial Challenges

Between late November and mid-December 2025, a consortium known as the Endeavor Investor Group, encompassing Endeavor Blockchain, LLC, PM Squared LLC, Cody Smith, and Joshua Allen Kilgore, acquired $4.38 million worth of Mawson Infrastructure Group Inc. (NASDAQ:MIGI) shares. The transactions occurred within a broad price spectrum of $4.03 to $12.00…

Shake Shack COO Executes Stock Sale Amid Mixed Quarterly Results

Shake Shack COO Executes Stock Sale Amid Mixed Quarterly Results

Stephanie Ann Sentell, Chief Operations Officer at Shake Shack Inc., finalized the sale of 200 shares of Class A common stock on January 20, 2026, valued at $19,838 under a pre-established trading plan. The transaction occurred despite the company’s recent fourth-quarter revenue falling slightly below analyst expectations. Shake Shack also announce…

Guardant Health's Chief People Officer Divests Nearly $1 Million in Shares Amid FDA Milestone and Analyst Upgrades

Guardant Health's Chief People Officer Divests Nearly $1 Million in Shares Amid FDA Milestone and Analyst Upgrades

Terilyn J. Monroe, Chief People Officer of Guardant Health, divested 8,571 shares valued at approximately $977,900 on January 21, 2026, amid a backdrop of encouraging FDA approval and positive analyst sentiment. The transactions occurred at prices ranging from $112.34 to $115.70 per share. Guardant Health has recently achieved FDA clearance for its…

Enliven Therapeutics CSO Joseph Lyssikatos Disposes of $535K in Shares Amid Promising CML Trial Data

Enliven Therapeutics CSO Joseph Lyssikatos Disposes of $535K in Shares Amid Promising CML Trial Data

Joseph P. Lyssikatos, Chief Scientific Officer at Enliven Therapeutics, executed stock sales totaling $535,098 through a pre-set trading plan, amidst the company's strong share performance and encouraging clinical trial updates for its chronic myeloid leukemia treatment. These transactions, reported in a recent SEC filing, reflect ongoing insider a…

Oragenics Director Executes Share Sale Amid Low Stock Pricing

Oragenics Director Executes Share Sale Amid Low Stock Pricing

Oragenics Inc experienced a director-led transaction involving the sale of a modest number of shares alongside the acquisition of a substantial quantity of stock options. While the company's stock has suffered a pronounced decrease over the past year, financial metrics indicate a solid liquidity position. Investors may find current valuations intri…